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Astrocytic atrophy as a pathological feature of Parkinson’s
disease with LRRK2 mutation
Paula Ramos-Gonzalez1,2, Susana Mato1,2,3,4, Juan Carlos Chara1,2,3, Alexei Verkhratsky 2,5,6, Carlos Matute 1,2,3 and
Fabio Cavaliere1,2,3✉
The principal hallmark of Parkinson’s disease (PD) is the selective neurodegeneration of dopaminergic neurones. Mounting
evidence suggests that astrocytes may contribute to dopaminergic neurodegeneration through decreased homoeostatic support
and deficient neuroprotection. In this study, we generated induced pluripotent stem cells (iPSC)-derived astrocytes from PD
patients with LRRK2(G2019S) mutation and healthy donors of the similar age. In cell lines derived from PD patients, astrocytes were
characterised by a significant decrease in S100B and GFAP-positive astrocytic profiles associated with marked decrease in astrocyte
complexity. In addition, PD-derived astrocytes demonstrated aberrant mitochondrial morphology, decreased mitochondrial activity
and ATP production along with an increase of glycolysis and increased production of reactive oxygen species. Taken together, our
data indicate that astrocytic asthenia observed in patient-derived cultures with LRRK2(G2019S) mutation may contribute to neuronal
death through decreased homoeostatic support, elevated oxidative stress and failed neuroprotection.
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INTRODUCTION
Parkinson’s disease is the second most common neurodegenera-
tive disorder with unknown aetiology1. Age is the principal risk
factor for PD, which affects around 1% of people older than 65
years2. The progressive death of dopaminergic neurones in the
substantia nigra pars compacta (SNpc) and the appearance of
protein deposits in a form of Lewy bodies (LB) mainly composed
by α-synuclein (α-syn) represent two major histopathological
hallmarks of PD3–5. Although the disease is mostly idiopathic, 10%
of the cases appear related to specific mutations in different
genes. The G2019S mutation in Leucine Rich Repeat Kinase 2
(LRRK2) gene is the most common cause of the familial PD6. This
mutation leads to an idiopathic phenotype of the disease albeit, in
certain cases, with the absence of LB7. The G2019S mutation is the
most frequent pathogenetic mutation in the overall LRRK2-PD
population8. This mutation occurs in the kinase domain of LRRK2,
leading to an increase in the activity of the enzyme9, which has
been shown to affect mitochondrial functionality, cytoskeletal
dynamics, response to reactive oxygen species (ROS) production,
and autophagy10,11.
Fibroblasts from PD patients carrying the G2019S mutation
showed abnormal mitochondrial morphology12. Similarly, over-
expression of wild-type LRRK2 in SH-SY5Y neuroblastoma cells
caused mitochondrial fragmentation, which was further enhanced
when the R1441C and G2019S mutations were expressed13.
Overexpression of LRRK2G2019S mutation in SH-SY5Y cells causes
mitochondrial uncoupling, leading to membrane depolarisation
and increased oxygen consumption14. The LRRK2G2019S mutation
also delays the digestion of dysfunctional mitochondria and the
initiation of mitophagy15.
Numerous studies have established a connection between
LRRK2 and both microtubules (MTs) and filamentous actin
(F-actin). A high-throughput screening performed to reveal LRRK2
interactome identified proteins involved in actin filament
assembly, organisation, rearrangement, and maintenance, sug-
gesting that the biological function of LRRK2 is linked to
cytoskeletal dynamics16. The same study demonstrated that
LRRK2 binds to F-actin and modulates F-actin assembly in mouse
primary dopaminergic neurones in vitro. This suggests that
morphological changes and abnormalities in neurites outgrowth
and branching may be consequences of LRRK2-modulation of
cytoskeletal dynamics.
Thus, analysis of PD pathogenesis has been mostly focused on
the mechanisms underlying ventral midbrain dopaminergic
neurones (vmDAn) degeneration and death. Neuronal survival,
however, is defined by multiple neuroprotective mechanisms
expressed in astrocytes, the principal homoeostatic and defensive
cells of the central nervous system17–19. Astrocytes density in the
SN is relatively low20, which may strain their ability to adequately
support and protect neurones. In PD, in contrast to other α-
synucleopathies, astrocytes do not mount reactive astrogliosis21,
an evolutionary conserved defensive response; rather, astrocytes
become dysfunctional and lose their protective capabilities22.
Astroglial atrophy, asthenia and loss of homoeostatic and
protective function contribute to several neurodegenerative and
psychiatric diseases23. A recent study demonstrated that the
treatment of LRRK2G2019S transgenic mice with α-syn increases the
expression of endoplasmic reticulum (ER) stress proteins in
astrocytes thus affecting neurites length and neuronal viability,
supporting the idea that ER stress in PD astrocytes can aggravate
neuronal damage24.
In this study, we have generated and characterised human iPS-
derived astrocytes (hiA) from PD patients carrying LRRK2G2019S
mutation. These PD astrocytes display an atrophic morphology
with decreased complexity, as well as altered mitochondrial
functionality that results in higher basal protein oxidation. As a
consequence, PD astrocytes show reduced mitochondrial meta-
bolism and increased glycolytic activity. Overall, we suggest that
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LRRK2G2019S mutation in astrocytes induces mitochondrial unba-
lance, leading to cell autonomous and non-autonomous damage
that ultimately translates to or exacerbates neurodegeneration.
Our results highlight an improvement of astroglial functionality as
a relevant therapeutic target.
RESULTS
Generation of patient-derived astrocytes from dermal
fibroblasts
Skin fibroblasts from two patients with LRRK2G2019S mutation and
two healthy donors (Supplementary Table 1) were reprogrammed
and differentiated to mature astrocytes. Fibroblast were repro-
grammed using the episomal Sendai viral vector bearing the
Yamanaka factors Klf4-Oct3/4-Sox2 (KOS), L-Myc and Klf4 (see
Supplementary Fig. 1 for protocol details). Fibroblasts were
expanded in Geltrex until they formed colonies positive for the
pluripotent markers Sox2, Oct4 and Nanog (Supplementary Fig. 2).
To further potentiate the formation of iPSC, colonies were picked
and expanded for 2–4 days in human recombinant laminin-521
(LN521). LN521 is normally expressed in the human embryo at the
inner cell mass and replicates the human stem cell niche in vitro
stabilising pluripotent gene expression. At this stage and before
neural induction, iPSC can differentiate to the three germ layer as
evidenced by the expression of Neurone-specific class III β-tubulin
(Tuj1 for ectoderm), smooth muscle actin (SMA for mesoderm)
and alpha-Fetoprotein (AFP for endoderm) (Supplementary Fig. 2).
To induce the differentiation to NSC, neural rosettes were
cultured with a 50%:50% mixture of laminin 211 (LN211) and
laminin 111 (LN111) coating. Unlike LN521, these two laminins
are mostly expressed in extra-embryonic membranes and
promote cell differentiation. In our culture conditions, NSCs were
differentiated to astrocyte progenitor cells in 21 days. Subse-
quently, astroglial precursors were further differentiated into
mature astrocytes (see Material and Methods) while maintaining
the coating with LN211/LN111 (50%:50%). After 60–75 days of
maturation, cells were fixed and stained with the astrocyte marker
GFAP. Maturation efficiency was evaluated by cytofluorimetry
assay (Supplementary Fig. 3) demonstrating 95%–98% of astro-
cyte differentiation. Astrocyte differentiation was also confirmed
by immunofluorescence with antibodies to GFAP and S100B,
whereas expression of MAP2 and β-III tubulin (for neurones) and
NG2 (for non-astrocyte glia) was absent or minimal (Fig. 1a). The
hiA also expressed the functional markers EAAT2 (glutamate
transporter) and CD49f, with undetectable differences between
healthy subjects and PD donors (Fig. 1b). All generated lines from
the four donors (healthy and PD) displayed neither genetic nor
structural variations in somatic and sex chromosomes as
demonstrated in Supplementary Fig. 4.
Fig. 1 Astrocytic marker expression in hiA. a hiA were maturated for 60 days in LN211/LN111 and fixed for immunofluorescence. All cell
cultures, from healthy (Ctrl1-2) and patient (PD1-2) donors, were positive for GFAP and S100β expression, whereas neuronal (MAP2 and β-III-
Tub) and non-astrocyte-glial (NG2) markers were nearly absent. White staining shows nuclei labelling by DAPI. b hiA co-immunostaining of
GFAP with CD49f and EAAT2 in healthy (Ctrl) and patient (PD) donors. The picture is representative of two Ctrls and two PD cell lines. Scale bar
is 25 μm. Photographs are representative of at least five experiments.
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Morphology of PD astroglia
We observed a striking difference in the morphology between
healthy and PD astrocytes (Fig. 2a–c). The surface area and
perimeter of GFAP-positive profiles of PD-derived astrocytes were,
respectively, 60% and 45% smaller when compared to healthy
cells, as measured by high-content screening (Fig. 2d–e). Similar
data (decrease in surface area and perimeter by 69% and 50%;
data not shown) were obtained by manual measurements using
the image software Fiji. Astrocytes from PD patients showed a
lower complexity with significant reduction in number or
complete absence of primary and secondary processes (Fig. 2f),
as evidenced by high-content screening analysis (35% lower than
healthy astrocytes), suggesting a decreased structural capacity for
supporting neurones. Decreased complexity of PD-derived astro-
cytes was also confirmed by Sholl analysis. As shown in Fig. 2g,
astrocytes derived from PD donors exhibit 61% less intersections.
Morphological atrophy in PD cultures was not detected in
fibroblasts; moreover, we did not detect differences during the
iPSC colony formation, but only after astrocyte differentiation
(data not shown), suggesting a specificity for the astrocytic
phenotype.
Functional characterisation of PD astrocytes
We next characterised functional properties of hiA. Astroglial
function and reactivity are tightly integrated with the dynamics of
cytosolic and mitochondrial Ca2+ concentrations controlling
bioenergetics; abnormal astrocytic Ca2+ signalling is increasingly
recognised as a key process in neurodegenerative conditions25–27.
Thus, we analysed Ca2+ dynamics in PD astroglia. Neither healthy
nor PD astrocytes generated spontaneous Ca2+ transients under
our experimental conditions and we found no difference in resting
cytoplasmic Ca2+ concentration ([Ca2+]i) between healthy and PD
hiA (Fig. 3a–b). Application of 100 μM ATP (an archetypal activator
of astroglial Ca2+ signalling) evoked transient [Ca2+]i elevation
(Fig. 3c–d) confirming the presence of functional purinergic
receptors coupled to astrocytic Ca2+ signalling machinery. In PD
astrocytes we observed a tendency (which did not reach the level
of significance) of reduction in amplitude and integral of Ca2+
transients in response to ATP (Fig. 3c–d). It has to be noted
however, that control hiA lines tested in this study displayed
marked differences in the amplitude of ATP-induced Ca2+
transients. We further tested mitochondrial membrane polarisa-
tion by imaging the quenching of the mitochondrial membrane
potential probe Rhodamine 123 in the presence of FCCP, which
revealed significant differences between control and PD hiA lines
(p= 0.0365); (Fig. 3e–f). Taken together, these finding confirm that
hiA, with differences between healthy and PD astrocytes, express
functional receptors for ATP, typical astrocytic Ca2+ signalling
machinery; the PD-derived astrocytes also demonstrated signs of
mitochondrial malfunction.
Fig. 2 Cell morphology analysis of PD astroglia. Cells from healthy (Ctrl1-2 in a) and patients (PD1-2 in b, c) donors were fixed after 60 days
of maturation and stained with GFAP antibodies. Images in c illustrate a higher magnification of a subfield in b. Morphological analysis was
performed by high-content screening (d–f) and Sholl analysis (g) as described in Materials and Methods. d–f histograms showing astrocyte area
(as a means of squared μm in d), perimeter (as a means of linear μm in e) and complexity (as a means of arbitrary units-au- of shape P2A in f).
In g is expressed the total number of intersections with concentric rings of Sholl grid (5 μm apart) after GFAP immunostaining of controls and
PD astrocytes. Data are presented as mean values ± SEM with n= 4.
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Mitochondrial impairment in PD astrocytes
It is well known that LRRK2 protein interacts with mitochondrial
membranes and affects mitochondrial respiration13,28. We, thus,
analysed mitochondrial metabolism in healthy and in PD
astrocytes using Seahorse technology. We first measured the
mitochondrial oxygen consumption rate (OCRs) of hiA in a live-cell
metabolic assay (Fig. 4a). PD astrocytes showed lower OCRs in
both basal (Fig. 4b) and maximal (Fig. 4c) respiration paradigms,
when compared to healthy cells. PD astrocytes also produced less
ATP (Fig. 4d). We did not, however, observe significant differences
between healthy and PDs astrocytes in terms of spare respiratory
capacity or proton leak (Fig. 4e–f). Consistent with a mitochondrial
respiration deficit, PD astrocytes displayed increased glycolytic
capacity as determined by changes in the extracellular acidifica-
tion rate (ECAR) (Fig. 5a), both in basal (Fig. 5b) and in
compensatory glycolysis (Fig. 5c). Similarly, basal proton efflux
rate (PER, the measure of extracellular acidification, Fig. 5d), but
not the PER derived from glycolysis (Fig. 5e), was increased in PD
astrocytes. Collectively these results indicate that astrocytes in PD
switch from oxidative phosphorylation to the aerobic glycolytic
respiration.
Mitochondrial malfunction is frequently associated with aber-
rant morphology29 and, therefore, we compared intracellular
distribution and the ultrastructure of mitochondria in healthy and
PD astrocytes. Mitochondrial distribution and gross morphology
was visualised by staining with Rhodamin 123. In healthy
astrocytes, mitochondria were elongated and interconnected,
forming a homogenous network distributed throughout the entire
cytoplasm, being present in the soma and in the principal
processes (Fig. 6a). In contrast, PD astrocytes had fewer
mitochondria, which were apparently more fragmented and
mainly concentrated in the perinuclear region; in addition
mitochondria were absent from short processes (Fig. 6a). The
very same distribution pattern was observed after staining with
Mitotracker (Supplementary Fig. 5), which demonstrates evident
perinuclear concentration of mitochondria in PD astrocytes.
Ultrastructural analysis of mitochondria (Fig. 6b), revealed further
Fig. 3 Cytosolic Ca2+ responses to ATP and FCCP in human astrocytes. a–b Time-courses show basal cytosolic Ca2+ responses in control
and PD hiA loaded with fura-2 (n= x-y cells). c Ca2+ responses evoked by ATP (100 μM) in hiA (n= x-y cells). d Comparison of the area under
the curve (AUC) calculated for each experimental condition (n= 3 cultures). e–f Measurement of mitochondrial membrane potential in hiA.
*p= 0.0365. One-way ANOVA followed by Newman–Keuls tests. Ctrls, control. PDs Parkinson´s disease. Data are presented as mean values ±
SEM with n= 3.
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differences between the healthy and PD astrocytes. The measure-
ment of the circularity, usually used as an index of ROS
production, demonstrated that mitochondria in PD astrocytes
were more rounded than in the control cells (Fig. 6c). Accordingly,
the Aspect Ratio (the major axis divided the minor axis of the
mitochondria) was higher in healthy astrocytes indicating the
presence of more elongated mitochondria.
According to the hypothesis by which fragmented mitochon-
dria are associated with higher levels of ROS29,30, we investigated
astrocytic metabolic profile. Using Oxyblot analysis, we measured
the carbonyl groups of total proteins extracted from healthy and
diseased lines as a readout of the oxidative status of the proteins.
We found higher amount of oxidised proteins (32%) in PD
astrocytes when compared to the controls (Fig. 7), suggesting a
basal oxidative status of astrocytes in PD higher than in healthy
astrocytes. We may conclude, therefore, that LRRK2G2019S muta-
tion corresponds to a general mitochondrial dysfunction in
astrocytes, with impaired mitochondrial respiration, cellular
localisation and mitochondrial ultrastructure.
DISCUSSION
To study human diseases, the “humanised” experimental prepara-
tions are essential; even the most sophisticated animal models of
human pathologies are not faithful replicas31,32. In this paper, we
analysed morphological characteristics and metabolic profile of
astrocytes derived from iPSCs generated from PD patients bearing
the LRRK2G2019S mutation. Using different combinations of several
laminins coating, we obtained almost homogeneous cultures of
human astrocytes (95%–98%). The purity of cultures was
confirmed by citofluorimetry analysis (Supplementary Fig. 3). We
simulated the physiological conditions occurring during the
embryonic development by mixing laminins LN521 and LN511.
Fig. 4 Mitochondrial metabolism and respiration. a Oxygen
consumption rates (OCRs) of Ctrl and PD astrocytes. Oligomycin,
FCCP and rotenone (Rot) were added, respectively, after 20, 40, and
60min as respiratory chain blockers. OCRs are expressed in b–f as
pmol por minute after cell viability normalisation with calcein
staining. b Basal respiration, c maximal respiration and d ATP
production are reduced in PD astrocytes compared to the controls.
e Spare respiratory capacity and f H+ Leak do not show statistically
significant changes (n= 4). Statistical analysis was performed using
one-way ANOVA. Data are presented as mean values ± SEM.
Fig. 5 Glycolytic activity. a Extracellular acidification rate (ECAR) of
Ctrl and PD astrocytes. b Basal glycolysis, expressed as pmol/min of
glycolytic proton efflux rate (PER), c Compensatory glycolysis and
d Basal PER, expressed as pmol/min of PER, are increased in PD
astrocytes compared to the controls. e PER from glycolysis is used as
an internal control and it is similar in the four lines (n= 3). Statistical
analysis was performed using one-way ANOVA. Data are presented
as mean values ± SEM.
P. Ramos-Gonzalez et al.
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Both these laminins are expressed in the inner cell mass and
support survival and self-renewal of the pluripotent stem cells
through the interaction with α6β1 integrin and PI3/Akt activa-
tion33,34. In contrast, mature astrocytes express LN111 and
LN21135,36; activation of these two laminins supports cell
differentiation and specialisation, such as, for example, the
maintenance of the blood-brain barrier integrity36.
The role of astrocytes in pathological progress of PD is yet to be
fully characterised. Recent works conducted on some inflamma-
tory experimental paradigms have suggested two subtypes of
astrocytes, A1 and A2 with neurotoxic and neuroprotective
profiles37. The A1/A2 dichotomy has been based on correlative
analysis of limited number of genes detected for specific
conditions in the in vitro settings. This binary polarisation has
not been confirmed38–43 and, similarly to once popular, but now
discarded, M1/M2 microglial polarisation concept, has been
repudiated by neuroglial community44.
Nonetheless, early in vitro experiments have clearly demon-
strated that astrocytes protect and support survival of dopami-
nergic neurones45. Subsequent studies revealed that functional
exhaustion and loss of astroglial homoeostatic support are
dominant glial contribution to the PD, and the special definition
of “dysfunctional” astrocytes has been introduced22,46. Further-
more, analysis of post-mortem samples of susbtantia nigra
obtained from PD patients demonstrated significant decrease in
expression of astroglial markers compared to healthy controls47,48;
these findings being in general agreement with our concept of
astroglial atrophy linked to the disease. Astroglial asthenia,
atrophy and loss of homoeostatic and neuroprotective capacities
were noted in aging40 and in various neurodegenerative and
neuropsychiatric diseases23,49; astroglial atrophy thus represents a
defined class of astrogliopathies50.
Obtaining an almost pure population of iPSC-derived astrocytes
allowed us to study human astrocytes bearing pathophysiological
signature. We have found a prominent aberrant morphology of
Fig. 6 Analysis of mitochondrial morphology. a Mitochondrial staining with Rhodamin 123 of hiA cultures from healthy (Ctrl1-2) and
patients (PD1-2) donors . Images were taken with the confocal microscope Leica TCS STED CW SP8. Squared inlets represent a higher
magnification of the field. Scale bar 20 μm. b Representative images of mitochondrial ultrastructure in Ctrl and PD astrocytes. c Circularity is
measured considering 1 as the perfect circle and d aspect ratio (ratio of circularity vs. elongation) reveal a more rounded shape in PD astrocyte
mitochondria compared to the control. More than 100 mitochondria were analysed for each line. Statistical analysis was performed using one-
way ANOVA. Data are presented as mean values ± SEM.
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astrocytes derived from PD LRRK2G2019S patients. Differentiated
astrocytic cultures, obtained from both healthy and PD subjects,
expressed classical astrocyte markers (GFAP, S100B, CD49f and
EAAT2). The PD astrocytes, however, were characterised by
substantially smaller area and perimeter; they also show
diminished complexity of primary and secondary processes as
evidenced by high-content screening and Sholl analysis. These
morphological changes do not represent culture artefact because
this atrophy was observed only in fully differentiated astrocytes
and not at preceding derivation stages. Previously published study
of iPSCs-derived astrocytes with LRRK2G2019S mutation51 did not
found conspicuous morphological changes, although astrocytic
appearance was not analysed in detail. We assume that the use of
specific feeder layers (laminins) and smaller number of cell
passages in our protocol (differentiation to astrocyte proceeds
with weekly passages) diminishes cell reactivity thus reliably
revealing cell morphology. Our findings of pronounced morpho-
logical atrophy in human iPSCs parallel recent demonstration of
similar morphological atrophy in iPSC-derived astrocytes gener-
ated from early familial and late sporadic AD patients52.
Morphological atrophy of astrocytes is arguably associated with
neuronal damage (due to failed homoeostatic support) and
aberrant synaptic connectivity manifest in neurodegenerative
and psychiatric diseases (for a review see ref. 50). In many cases,
astrocytic atrophy precedes cell death and neuronal degeneration.
For example, in acute excitotoxic neurodegeneration and ALS,
morphological aberrations are accompanied with the down-
regulation of glutamate transporters and increased excitotoxi-
city18. Morphological atrophy in AD has been described in animal
models54–56, in human iPSC-derived astrocytes from patients53, in
deprenil-based brain imaging in patients57, and in post-mortem
brain at late stages of the disease (Rodriguez and Verkhratsky,
unpublished results). In our culture conditions atrophic astrocytes
from PD patients showed normal viability, as demonstrated by
expression of classical markers (Fig. 1) and by physiological [Ca2+]i
dynamics (Fig. 3). At the same time PD astrocytes demonstrate
reduced mitochondrial functionality (Figs 4–6). Mitochondrial
aberrations and morphological atrophy may explain why astro-
cytes in PD with LRRK2G2019S mutation fail to support and protect
neurones. This loss of function became even more evident in
specific brain regions, specifically for substantia nigra pars
compacta and striatum, where astrocytic density is lower
compared to other regions20. Furthermore, astrocytes from
substantia nigra seem to be unusually vulnerable to ischaemic
attack58 and oxidative stress59. Loss of astroglial support may act
as an exacerbating factor in neurodegenerative process; chroni-
cally malfunctional astroglia was suggested to contribute to death
of dopaminergic neurones60. It is early to conclude that astrocytic
atrophy is the hallmark of PD until the same astrocytic atrophy is
characterised in situ in patient’s brain tissues or in astrocytes
derived from other mutations. Detailed analysis of astrocyte
morphology should be performed in other regions of the brain
that are related with dopaminergic degeneration (e.g., subtha-
lamic nucleus or globus pallidum) and not only in degenerating
regions where astrocytes are pathologically remodelled.
Mutation in the LRRK2 gene may be specifically responsible for
both aberrant morphology and mitochondrial dysfunction
observed in LRRK2G2019S hiA. Abnormalities in neurites outgrowth
and branching are among the earliest pathological phenotypes
observed in LRRK2 mutations61,62. It has been initially proposed
that the origin of these morphological changes could be related to
an apoptotic process62; however, further studies provided
evidence for an association of LRRK2 with tubulin/actin, thus
suggesting that morphological changes may be consequences of
LRRK2-modulation of cytoskeletal dynamics63. Several lines of
evidence suggest the relationship of LRRK2 protein with the
cytoskeleton: (i) The GTPase domain of LRRK2 protein can pull-
down α/β tubulin from cell lysates of mouse fibroblasts and
human embryonic kidney64; (ii) LRRK2 co-precipitates with β
tubulin from wild-type mouse brain and (iii) Recombinant LRRK2
can phosphorylate β tubulin in vitro65. High-throughput screening
of LRRK2 interactome revealed proteins of the actin family and of
the actin-regulatory network as interactors of LRRK2 in actin
polymerisation in vitro16. We presume therefore, that the atrophy
observed in PD LRRK2G2019S astrocytes could be a consequence of
the mutated LRRK2 protein breakdown that becomes unable to
properly modulate cytoskeletal dynamics. Similarly, LRRK2 muta-
tion can be responsible for mitochondrial dysfunction and
fragmentation, as already observed in fibroblasts, neural stem
cells or neuroblastoma cell lines13,66–68. Multiple studies demon-
strated that LRRK2 loss of function, associated with G2019S and
R1441G mutations impair mitochondrial oxidative state increasing
the neuronal susceptibility to oxidative stress damage69–71. One
possible explanation might be a mitochondrial DNA damage
induced by the LRRK2 mutations, which was observed in midbrain
cultures and PD patient-derived lymphoblastoid cell lines72.
The observations that LRRK2 mutation may be responsible for
morphological atrophy and mitochondrial malfunction, indicate
possible mechanism associated with reduced neuroprotection in
this mutation carriers. A recent observation demonstrated that
G2019S mutation in hiA alters the astrocyte-to-neurone commu-
nication mediated by extracellular vesicles73. In this work, the
LRRK2 mutation in astrocytes was claimed to affect morphology
and the content of extracellular vesicles and multivesicular bodies
(MVB). The authors found that neurones incorporated astrocyte
MVB with an abnormal accumulation of key PD-related proteins
such as LRRK2 and phospho-S129 α-Syn. Dopaminergic neurones
incorporating the dysfunctional MVB released by the LRRK2G2019S
astrocytes showed an aberrant morphology73.
In this study, we propose an hallmark for PD with LRRK2G2019S
mutation. Our hypothesis postulates that astrocytes with this
mutation fail to support neurones because of loss of homoeostatic
support resulting from substantial morphological atrophy and loss
of complexity; in addition, astrocytes demonstrated mitochondrial
dysfunction that also affects their neuroprotective capabilities.
METHODS
Human samples
Human fibroblasts were obtained from two healthy donors (Ctrl1 was
purchased from AXOL and Ctrl 2 from the Coriell stem cell bank) and two
Parkinson´s disease patients with LRRK2G2019S mutation (PD1 from the
Coriell stem cell bank and PD 2 provided by the BioDonostia Hospital, San
Fig. 7 Detection of oxidised proteins in total astrocyte protein.
Total proteins from hiA cultures were extracted after 60 days of
in vitro maturation. Oxidised proteins are visualised after Western
blot analysis as the conversion of the 2,4-dinitrophenol (DNP) to 2,4-
dinitrophenylhydrazine (DNPH). Each sample is loaded as a negative
control (Neg) with non-derivatised procedure. DNPH levels were
normalised with total proteins stained with Red Ponceau.
P. Ramos-Gonzalez et al.
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Sebastian, Spain) (Supplementary Table 1). Control patients who matched
PD donors in age and gender did not show any neurological symptoms. All
procedures with human cells were approved by the National and local
ethical committees (with code M30_2018_030) according to the National
law 14/2007 on Biomedical research.
Generation of human induced astrocytes (hiA)
Fibroblasts were grown in DMEM F12 (Gibco/ThermoFisher, Spain) and
infected with the CytoTune iPS 2.0 Sendai Reprogramming Kit (Thermo-
fisher, Spain) as described in Supplementary Fig. 1. The commercial Sendai
virus expressed the key genetic factors necessary for reprogramming
somatic cells into iPSCs (Klf4/Oct3-4/Sox2-KOS, hc-Myc, Klf4). Infection
efficiency was evaluated by co-infection with a EmGFP fluorescent reporter
plasmid provided by the kit. Seven days later, transduced fibroblasts were
seeded in Geltrex (ThermoFisher, Spain) in Essential 8 Flex medium (E8,
Gibco/ThermoFisher, Spain). E8 medium was changed every day for
21 days until we observed the formation of iPSC colonies. Colonies were
manually isolated using a 27G Braun Sterican Needle and replated in
laminin-521 (LN521-Biolamina, Sundbyberg Sweden) with E8 medium and
ROCK inhibitor (Y-27632; Millipore, Madrid, Spain). The day after, ROCK
inhibitor was removed and replaced with fresh medium. Colonies were
sequentially isolated and re-suspended at single cell level. Embryoid bodies
(EB) were generated (Supplementary Fig. 2) after re-suspending the iPSC
colonies in Essential 6 medium (E6, Gibco) for 2–4 days in the
AggrewellTM800 plates (StemCell, Grenoble, France). Half-medium in the
microwells was replaced daily with fresh medium. EBs were then seeded in
a LN521/LN211 mix (50% each) (Biolamina) and the differentiation to
neural precursor cells (NPC) as neural rosettes was promoted using the
STEMdiff Neural Induction Medium (Stemcell). After 7 days, neural rosettes
were selected and detached using the STEMdiff Neural Rosette Selection
Reagent (Stemcell). Cells were incubated for 2 h with this reagent at 37 °C
with 5% CO2 and then, mechanically re-suspended at single cell level and
seeded in LN211/LN111 (50% each) (Biolamina). Differentiation of NPC to
progenitor astrocytes was triggered using the astrocyte differentiation
medium (STEMdiff astrocyte differentiation #100-0013, StemCell). To
maintain the appropriate cell density (70% of confluence) cells were
passed every week in the same coating mix during 21 days. Maturation.
Finally, astrocytes progenitor cells were maturated in the Astrocyte
Maturation Medium (STEMdiff astrocyte maturation #100-0016, StemCell)
for 60 to 75 days. During the whole protocol, the correct state of the cells
in each step was evaluated using the EVOS FL microscope (Life
Technologies, AME4300). See Supplementary Fig. 1 for an overview of
simplified protocol steps.
Cytofluorimetry assay
Cells (500.000) were detached with TryPLE (Sigma, Spain) and fixed as a
single cell suspension with PFA 4% for 10min. Cells were washed in
phosphate-buffered saline (PBS) at 400 x g for 5 min and re-suspended in
blocking solution (0.5 g BSA in PBS with 0.01% Triton (PBS-T) with agitation
overnight at 4 °C. The following day cells were washed and incubated with
the primary antibody goat anti-GFAP (Abcam, 53554) for 2 h at 4 °C. After
further wash for 5 min in PBS-T 0.01% cell suspension was incubated with
the secondary conjugated antibody Alexa fluor 488 donkey anti-goat for
1 h at 4 °C. After a further wash with PBS-T 0.01%, cells were finally re-
suspended in PBS 1x. Cells were analysed in the BD FACSJazz (USB, inFlux
Compact) analyser using the Blue 488 laser. Unstained cells were gated
and used as a negative control.
Calcium imaging
Cytosolic calcium (Ca2+) levels were estimated by the 340/380 ratiometric
microfluorimetry as described previously74. Astrocytes were loaded with
fura-2 AM (5 μM; ThermoFisher/Invitrogen) for 20 at 37 °C and subse-
quently washed in the recording solution containing 137mM NaCl, 5.3 mM
KCl, 0.4 mM KH2PO4, 0.35 mM Na2HPO4, 20 mM HEPES, 4 mM NaHCO3,
10mM glucose, 1 mM MgCl2, 2 mM CaCl2 (pH 7.4) to allow de-
esterification. In experiments with FCCP, Ca2+ was omitted from the
recording solution. Experiments were performed in a coverslip chamber
continuously perfused with buffer at 1 ml/min by exposing the cells to ATP
(100 μM) or FCCP (1 μM). The perfusion chamber was mounted on the
stage of a Zeiss (Oberkochen, Germany) inverted epifluorescence
microscope (Axiovert 35), equipped with a 150W xenon lamp Polychrome
IV (T.I.L.L. Photonics, Martinsried, Germany), and a Plan Neofluar 403 oil
immersion objective (Zeiss). Cells were visualised with a high-resolution
digital black/white CCD camera (ORCA, Hamamatsu Photonics Iberica,
Barcelona, Spain) and images were acquired every 5 s. Image acquisition
and data analysis were performed using the AquaCosmos software
programme (Hamamatsu Photonics Iberica). Intracellular Ca2+ measure-
ments were expressed as the ratio of F340/F380 and normalised to baseline
values. Results for statistical comparison were calculated as area under the
curve (AUC) of the response for each cell from the start of each compound
application.
Immunofluorescence
Cell cultures were fixed in 4% para-formaldehyde (Merck/Sigma),
permeabilised with 0.1% Triton (Sigma) and non-specific epitopes were
blocked with 5% normal goat serum in PBS. Primary antibodies
(Supplementary Table 2) were incubated overnight and then washed
three times with 0.1% Triton in PBS. Secondary conjugated antibodies
Alexa 488, Alexa 594, Alexa 647 or Alexa 405 (Invitrogen, 1:500), were
incubated for 1 h in the dark at room temperature. After three washes with
0.1% Triton in PBS, cell nuclei were counter-stained for 1 min with DAPI
(ThermoFisher). Finally, coverslips were mounted with Glycergel (Dako,
Barcelona, Spain) and analysed using the confocal microscope Leica TCS
STED CW SP8.
Morphological analysis by high-content screening
Cells were seeded in glass bottom Cellvis 24-well plates (Cellvis, Bilbao,
Spain) coated with LN111/LN211 (Biolamina). After fixation with 4% PFA for
8 min, cells were immunostained for GFAP expression (Goat anti-GFAP,
Abcam 53554). Alexa fluor Donkey anti-goat was used as a secondary
antibody. Images were taken with the CellInsight CX7 high-content
screening system (Thermo Scientific) using a 10x objective. Morphological
parameters for area (defined as the number of microns squared of the
object), perimeter (length of the boundary of the object) and ShapeP2A
(measure of the ratio of the perimeter squared of the object to four times)
were calculated with High-Content Analysis platform. More than 100 cells
per cell line were analysed.
Morphological assessment
Sholl analysis was performed with the public software Fiji75, to measure the
complexity of GFAP-positive human astrocytes. A transparent grid with
concentric circles (every 5 μm from the centre of the cell soma across the
whole radius) were superimposed onto the cells after immunofluorescence
with GFAP antiserum. Sholl measurements were obtained by quantifying
the number of intersections with each concentric circle.
Electron microscopy
Cells were fixed in 4% PFA for 10min and post-fixed in 3% glutaraldehyde
for 30min. After a wash in phosphate buffer (PB) samples were osmicated
(1% OsO4 in 0.1 M PB; pH 7.4) for 30min. After 3 x 10min washes in 0.1 M
PB, samples were dehydrated in graded ethanol concentrations (50%
to100%) to propylene oxide and embedded in epoxy resin (Sigma-Aldrich)
by immersion in decreasing concentration of propylene oxide (1:3 for
30min, 1:1 for 1 h and 3:1 for 2 h). Samples were then embedded in fresh
resin overnight and allowed to polymerise at 60 °C for 2 days. Following
visualisation at the light microscope, selected portions were trimmed and
glued onto epoxy resin capsules. Semi-thin sections (500 nm-thick were cut
from epoxy blocks using a Power Tome ultramicrotome (RMC Boeckeler,
Tucson, AZ, USA and stained with 1% toluidine blue. Ultrathin (50–60 nm
thick) sections were then cut with diamond knife (Diatome, Hatfield PA,
USA), collected on nickel mesh grids and stained with 4% uranyl acetate
for 30min and 2.5% lead citrate for electron microscope visualisation. For
Image Acquisition and analysis, electron microscopy images of mitochon-
dria were taken from randomly selected fields with a Jeol JEM 1400 Plus
electron microscope at the Service of Analytical and High-Resolution
Microscopy in Biomedicine of University of the Basque Country UPV/EHU.
Images were taken at a magnification of 12,000X. Circularity and aspect
ratio (ratio of circularity vs. elongation) were measured with Fiji-Software
using a self-made plug-in. More than 100 mitochondria were analysed for
each line.
Mitochondrial membrane potential (ΔΨm) measurement
Mitochondrial membrane potential (ΔΨm) of human astrocytes was
assessed by the Rhodamine 123 (Rh123) staining. Briefly, cells were
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seeded in 35mm glass bottom plates (Ibidi GmbH, Germany) at a mean
density confluence of 50–70% and loaded with 10 μM Rh123 at 37 °C and
5% CO2. After 15min cells were washed with 900 μl Hanks’ balanced salt
solution and analysed by time lapse every 15 s for 5 min using the confocal
microscope Leica TCS STED CW SP8. To establish the basal line, cells were
stimulated with 1 μM FCCP after the first 60 s. Fluorescence intensity after
FCCP treatment was measured with the Leica LASX Software and data
were analysed with GraphPad Prism 5 (San Diego, CA, USA).
Measurement of mitochondrial function and glycolytic activity
The oxygen consumption rate (OCR), as an indicator of mitochondrial
respiration, the extracellular acidification rate (ECAR), as indicator of
glycolytic activity, and the proton efflux rate (PER), which correlates with
lactate production, were measured with the Seahorse XF96 extracellular
flux analyser. For the analysis of mitochondrial respiration, human
astrocytes (30,000 cells/ mm2) were seeded in LN211/LN111 (Biolamina)
precoated wells. The day of the experiment, cell medium was changed to
Mito XF Medium (XF basal medium with phenol red, 0.001M piruvic acid,
0.002M glutamine, glucose 0.01 M, pH 7.4). The OCRs were obtained after
the sequential treatment with oligomycin (2 μM), FCCP (1 μM), and
rotenone combined with antimycin A (0.5 μM). To measure the glycolytic
activity, we used the same protocol with the following modifications. The
day of the experiment, cell medium was changed to Glico XF Medium
without phenol red (DMEM Base Medium without Phenol Red with 5mM
HEPES, 10 mM glucose, 1 mM sodium pyruvate, 2 mM glutamine, pH 7.4 at
37 °C). The ECAR and PER were obtained after the sequential treatment
with rotenone combined with antimycin A (0.5 μM) and 2DG (50mM),
respectively. Four replicates were performed for each condition or cell type
for every experiments (n= 3). Data was analysed with the Wave
2.4.0 software.
Western blot for detection of oxidatively modified proteins
(oxyblot)
Astrocytes (30.000/well) were maturated for 60 days in 24-well plates
coated with LN211/LN111 (Biolamina) and solubilised for 20 min with
equal volume of 2x Extraction Buffer. Samples were prepared according
to manufacturer’s instruction with all the reagents provided in Oxidised
protein western blot detection kit (ab178020; Abcam). Briefly, the
carbonyl groups in the protein side chains were derivatised to 2,4-
dinitrophenylhydrazone (DNP-Hydrazone) by reaction with 2,4-dinitro-
phenylhydrazine (DNPH). Two aliquots of each sample were prepared to
be analysed simultaneously. One aliquot was treated with “derivatisa-
tion reaction” (DNPH Solution) and the other control aliquot was treated
with “derivatisation control reaction”. Protein concentration was
quantified with a detergent-compatible assay reagent (Pierce BCA
Protein Assay Kit) according to the manufacturer’s instructions (Thermo-
Fisher Scientific). Proteins loading was normalised after Red Ponceau
staining. All blots derive from the same experiment and they are
processed in parallel.
Statistical analysis
Results are expressed as mean ± standard error of the mean (S.E.M) with n
corresponding to the number of cells or cultures tested. Data were
analysed with Excel (Microsoft, Seattle, WA, USA) and GraphPad Prism
software. Statistical significance between datasets was tested using one-
way analysis of variance (ANOVA) followed by Newman–Keuls multiple
comparison test, with a significance threshold of p < 0.05.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding
author upon reasonable request.
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